Mesenchymal stem cells alleviate inflammatory responses through regulation of T-cell subsets.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Ji W;Ji W;Ji W; Sun L; Sun L; Wang D; Wang D; Zhu W; Zhu W; Zhu W
  • Source:
    European journal of pharmacology [Eur J Pharmacol] 2024 Nov 15; Vol. 983, pp. 176996. Date of Electronic Publication: 2024 Sep 12.
  • Publication Type:
    Journal Article; Review
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0712 (Electronic) Linking ISSN: 00142999 NLM ISO Abbreviation: Eur J Pharmacol Subsets: MEDLINE
    • Publication Information:
      Publication: 2005- : Amsterdam : Elsevier Science
      Original Publication: Amsterdam, North Holland Pub. Co.
    • Subject Terms:
    • Abstract:
      Immune-mediated inflammatory disease (IMID) is a complex disorder characterized by excessive immune responses involving T cells and their subsets, leading to direct tissue damage. T cells can be broadly categorized into CD4 + T cells and CD8 + T cells. CD4 + T cells are composed of several subsets, including T helper (Th)1, Th2, Th9, Th17, Th22, follicular helper T cells (Tfhs), and regulatory T cells (Tregs), while effector CD8 + T cells consist mainly of cytotoxic T cells (CTLs). Current therapies for IMID are ineffective, prompting exploration into mesenchymal stem cells (MSCs) as a promising clinical treatment due to their immunomodulatory effects and self-renewal potential. Recent studies have shown that MSCs can suppress T cells through direct cell-to-cell contact or secretion of soluble cytokines. Nevertheless, the precise effects of MSCs on T cell subsets remain inadequately defined. In this review, we summarize the most recent studies that have examined how MSCs modulate one or more effector T-cell subsets and the mechanisms behind these modifications in vitro and several mouse models of clinical inflammation. This also provides theoretical support and novel insights into the efficacy of clinical treatments involving MSCs. However, the efficacy of MSC therapies in clinical models of inflammation varies, showing effective remission in most cases, but also with exacerbation of T-cell-mediated inflammatory damage in some instances.
      Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Sun li reports financial support was provided by Jiangsu National Natural Science Foundation and National Natural Science Foundation of China. Zhu wei reports financial support was provided by National Natural Science Foundation of China. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Immune-mediated inflammatory diseases; Inflammation; Mesenchymal stem cells therapy; T cells
    • Publication Date:
      Date Created: 20240914 Date Completed: 20241009 Latest Revision: 20241009
    • Publication Date:
      20241010
    • Accession Number:
      10.1016/j.ejphar.2024.176996
    • Accession Number:
      39277095